Luke Evnin, Director at Werewolf Therapeutics, Inc. (HOWL), sold 38,782 shares at $0.54 ($21K) on 2026-01-16, disclosed to the SEC on 2026-01-20.
Scheduled sale ($21k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| HOWL | SELL | 2026-06-10 | $28K | — | Filing → |
| HOWL | SELL | 2026-06-08 | $43K | — | Filing → |
| HOWL | SELL | 2026-06-03 | $64K | — | Filing → |